trending Market Intelligence /marketintelligence/en/news-insights/trending/Kytrs8kBgTJqiZqT0OdBIg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Flagship Pioneering launches biotechnology company Ring Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Flagship Pioneering launches biotechnology company Ring Therapeutics

Cambridge, Mass.-based venture capital firm Flagship Pioneering said it launched a new early-stage biotechnology company that would specialize in gene therapy.

Ring Therapeutics Inc. was founded by the healthcare-focused investor in 2017, and will now start operations with $50 million in funding commitment from Flagship Pioneering, which raised $824 million in March to support early-stage companies. Avak Kahvejian, a Flagship Pioneering partner, is Ring Therapeutics' founding CEO.

Ring Therapeutics is developing technology to overcome a range of limitations in current DNA and gene therapies, and plans to use its platform to develop more effective products for patients. The company is targeting therapeutic areas including genetic disorders, ophthalmology, oncology, metabolic disorders, hematology, central nervous system disorders and inflammatory diseases.

Flagship Pioneering operating partner Rahul Singhvi has been appointed as Ring Therapeutics' president. Until recently, Singhvi was the COO of Takeda Pharmaceutical Company Ltd.'s global vaccine business unit. Prior to Takeda, he was president and CEO of Novavax Inc., a Nasdaq-listed vaccine company.